Clinical Trials Directory

Trials / Terminated

TerminatedNCT03624907

Daily vs. Non-Daily SBRT for NSCLC

Consecutive Vs. Non-Consecutive Stereotactic Body Radiotherapy For Early Stage Non-Small Cell Lung Cancer

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
University of Florida · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if stereotactic body radiotherapy (SBRT) on non-consecutive days will increase the chances of curing non-small cell lung cancer when compared to daily treatment.

Detailed description

The purpose of this study is to determine if treatment with stereotactic body radiotherapy (SBRT) on non-consecutive days will improve the chance of curing non-small cell lung cancer compared to treatment with SBRT on consecutive days. In either case, the dose of radiation is the same. Non-consecutive treatments will be at least 40 hours apart and no more than 100 hours apart. The total course of treatment will be 8-12 days. Consecutive treatments will be daily over 4-5 days within one calendar week. The total course of treatment will be 4-5 days. The study team will assess if DNA from the tumor can be found in the blood to determine which patients respond quickest to radiotherapy. These results will not be made available to participants and will not change treatment.

Conditions

Interventions

TypeNameDescription
RADIATIONDaily Stereotactic Body RadiotherapyAfter randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
RADIATIONNon-Daily Stereotactic Body RadiotherapyAfter randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.

Timeline

Start date
2018-10-19
Primary completion
2021-06-16
Completion
2021-06-16
First posted
2018-08-10
Last updated
2021-10-04

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03624907. Inclusion in this directory is not an endorsement.